Vaxil Bio Ltd. VXL.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -36.35% | 151.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.35% | 151.58% | |||
| Operating Income | 36.35% | -151.58% | |||
| Income Before Tax | 40.77% | -119.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 40.77% | -119.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.77% | -119.08% | |||
| EBIT | 36.35% | -151.58% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 40.82% | -114.96% | |||
| Normalized Basic EPS | 40.16% | -84.85% | |||
| EPS Diluted | 40.82% | -114.96% | |||
| Normalized Diluted EPS | 40.16% | -84.85% | |||
| Average Basic Shares Outstanding | 0.00% | 27.64% | |||
| Average Diluted Shares Outstanding | 0.00% | 27.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||